The Abu Dhabi Investment Authority has backed the business for the first time.

Gossamer, a US-based biotechnology company that focuses on novel therapeutic products, has this week closed a $230m series B funding round.

First-time investors include the Abu Dhabi Investment Authority, Invus, the Baupost Group and Polaris Partners, while ARCH Venture Partners and Omega Funds have returned.